Drug Trial Radar · NCT00908310
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
Last checked: Nov 19, 2026Latest source record: Jul 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
213
Actual
Start
May 2009
Primary completion
Jun 2013
Study completion Sep 2013
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- Collaborators
- i3 Statprobe
- First posted
- May 25, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI. Omniscan will be administered intravenously at the medical discretion of the prescribing physician.
Conditions
- Chronic Kidney Disease
- Renal Insufficiency
Interventions
OmniscanDrug
OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Capture of Post-marketing Safety Information in Patients With Moderate Renal Insufficiency Undergoing Routine Contrast-enhanced MRI With Administration of OMNISCAN in Order to Assess the Risk for Developing Nephrogenic Systemic Fibrosis (NSF).Time frame: Greater than or equal to 7 days post contrast administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GE Healthcare
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.